Last updated: August 27, 2026
Kite Pharma, a Gilead Sciences company, is a leading commercial cell-therapy business with two approved CAR T products, Yescarta and Tecartus. Its strongest position is in large B-cell lymphoma, where Yescarta has established the largest commercial base among CD19-directed CAR T therapies. Kite’s principal risks are manufacturing complexity, hospital capacity, pricing pressure, treatment-center competition, safety management and the eventual erosion of exclusivity through patent challenges and competing cell therapies.
What is Kite Pharma’s market position in cell therapy?
Kite is one of the largest commercial developers of autologous CAR T-cell therapies. Its products are marketed in the United States, Europe and other major markets through Gilead’s global infrastructure.
| Company |
Product |
Target |
Principal indications |
Commercial position |
| Kite Pharma/Gilead |
Yescarta |
CD19 |
Large B-cell lymphoma, follicular lymphoma |
Leading commercial CAR T franchise |
| Kite Pharma/Gilead |
Tecartus |
CD19 |
Mantle cell lymphoma, acute lymphoblastic leukemia |
Established niche franchise |
| Bristol Myers Squibb |
Breyanzi |
CD19 |
Large B-cell lymphoma, CLL/SLL, follicular lymphoma |
Direct Yescarta competitor |
| Novartis |
Kymriah |
CD19 |
B-cell ALL, diffuse large B-cell lymphoma, follicular lymphoma |
Early entrant with broad regulatory history |
| Bristol Myers Squibb |
Abecma |
BCMA |
Multiple myeloma |
Competes in myeloma, not CD19 lymphoma |
| Legend Biotech/Janssen |
Carvykti |
BCMA |
Multiple myeloma |
High-growth myeloma CAR T |
| Iovance Biotherapeutics |
Amtagvi |
TIL therapy |
Melanoma |
Competing adoptive-cell therapy platform |
Yescarta generated approximately $1.57 billion in 2023 revenue, while Tecartus generated approximately $457 million, according to Gilead’s 2023 Form 10-K. Combined Kite cell-therapy product sales therefore exceeded $2 billion in 2023, excluding pipeline value and regional licensing economics (Gilead Sciences, 2024a).
Kite’s position is strongest in:
- Second-line large B-cell lymphoma.
- Third-line or later large B-cell lymphoma.
- Follicular lymphoma after multiple prior therapies.
- Mantle cell lymphoma.
- Commercialized treatment-center infrastructure.
- Manufacturing experience with autologous cell therapies.
How do Yescarta and Tecartus compare with competing CAR T products?
Yescarta versus Breyanzi
Yescarta and Breyanzi are the closest commercial competitors in large B-cell lymphoma. Both are CD19-directed autologous CAR T products, but they differ in construct design, manufacturing characteristics, regulatory history and treatment-center adoption.
Yescarta reached the market first in the United States for relapsed or refractory large B-cell lymphoma. It later received approval in second-line disease after the ZUMA-7 trial demonstrated a benefit over salvage chemotherapy followed by autologous stem-cell transplantation in eligible patients (FDA, 2022a).
Breyanzi gained a second-line large B-cell lymphoma indication after the TRANSFORM study. Its competitive positioning includes a differentiated cell-composition approach and expansion into chronic lymphocytic leukemia and small lymphocytic lymphoma.
| Metric |
Yescarta |
Breyanzi |
| Sponsor |
Kite/Gilead |
Bristol Myers Squibb |
| CAR target |
CD19 |
CD19 |
| Core lymphoma market |
Large B-cell lymphoma |
Large B-cell lymphoma |
| Second-line approval |
Yes |
Yes |
| Manufacturing model |
Autologous, centralized |
Autologous, centralized |
| Primary commercial advantage |
First-mover scale and treatment-center penetration |
Product differentiation and broadening label |
| Main risk |
Manufacturing capacity and competition |
Lower installed base than Yescarta |
Yescarta retains an important commercial advantage from physician familiarity, treatment-center relationships and cumulative real-world experience. Breyanzi places pressure on Kite through label expansion and differentiation in patient populations with limited treatment options.
Yescarta versus Kymriah
Kymriah was the first FDA-approved CAR T therapy and remains important in pediatric and young-adult B-cell acute lymphoblastic leukemia. Yescarta has a stronger position in adult lymphoma.
Kymriah’s principal strategic strength is its early regulatory history and broad clinical experience. Yescarta’s advantages are its lymphoma efficacy profile, commercial scale and expansion into earlier treatment lines.
Tecartus versus other CD19 therapies
Tecartus is differentiated by its mantle cell lymphoma and adult acute lymphoblastic leukemia indications. The mantle cell lymphoma market has become more competitive because of targeted therapies, including BTK inhibitors and non-covalent BTK inhibitors.
Tecartus faces a narrower opportunity than Yescarta, but its indication-specific data and use in heavily pretreated disease support continued commercial relevance. Its main competitive risks are earlier-line targeted therapies, bispecific antibodies and other cellular therapies.
What FDA approvals and exclusivity periods apply to Kite products?
The FDA approval history is central to Kite’s market position.
| Product |
FDA approval |
Initial indication |
Later expansion |
| Yescarta |
October 18, 2017 |
Relapsed or refractory large B-cell lymphoma |
Second-line large B-cell lymphoma; follicular lymphoma |
| Tecartus |
July 24, 2020 |
Relapsed or refractory mantle cell lymphoma |
Adult B-cell acute lymphoblastic leukemia |
Yescarta and Tecartus are biologics licensed under section 351(a) of the Public Health Service Act. Their regulatory exclusivity is distinct from patent protection.
For biologics approved under the Biologics Price Competition and Innovation Act, the reference product generally receives 12 years of reference-product exclusivity from first licensure, subject to statutory rules and FDA interpretation. That period does not prevent all follow-on competition in the same way as a small-molecule five-year new chemical entity period. Biosimilar applicants can begin certain preparatory activities before the end of the exclusivity period, and the practical launch date depends on patent litigation, settlement terms and regulatory approval (FDA, 2023a).
Yescarta’s 12-year reference-product exclusivity period runs approximately into 2029, depending on the FDA’s first-licensure determination. Tecartus’s corresponding period runs approximately into 2032. Patent rights may extend beyond or expire before these dates.
What patents protect Yescarta and Tecartus?
Kite’s cell-therapy patent estate is broader than a single composition-of-matter patent. Protection may cover:
- CAR designs.
- Antibody-binding domains.
- Hinge and transmembrane regions.
- Costimulatory domains.
- T-cell activation methods.
- Cell expansion processes.
- Vector construction.
- Transduction methods.
- Manufacturing controls.
- Cryopreservation and formulation.
- Methods of treating CD19-positive malignancies.
- Treatment combinations and patient-selection criteria.
The most valuable rights are generally those that protect the commercial product’s specific CAR architecture or manufacturing process. Method-of-use patents have narrower enforcement value because a competitor can sometimes design around an indication, label or treatment protocol.
Why the patent estate is difficult to evaluate
CAR T products combine biological components and manufacturing steps. A competitor may avoid a claim by changing:
- The single-chain variable fragment.
- The linker.
- The hinge.
- The costimulatory domain.
- The vector system.
- The culture conditions.
- The release specifications.
- The manufacturing sequence.
This creates a different risk profile from a traditional small-molecule product, where one active ingredient and a limited number of formulations often dominate the patent analysis.
Kite also relies on trade secrets and operational know-how. Chain-of-identity controls, closed-system processing, release testing, vein-to-vein logistics and quality systems can create practical barriers that are not visible in patent databases.
What is the Orange Book status of Yescarta and Tecartus?
Yescarta and Tecartus are biologics, so the Orange Book is not the primary patent reference for their exclusivity analysis. The FDA’s Purple Book and biologics patent-dispute framework are more relevant than conventional Orange Book listings.
For business planning, the relevant questions are:
- Which patents are identified in the biologics patent-exchange process?
- Which patents are enforceable against a proposed biosimilar or follow-on product?
- Which claims cover the marketed CAR construct?
- Which claims cover manufacturing rather than the active cellular product?
- Are any patents subject to terminal disclaimers, prosecution-history limitations or written-description vulnerabilities?
- Does a proposed competitor rely on a new process, a different construct or a different indication?
A standard Orange Book-style “last patent expiration” date is therefore less informative for Kite than a layered analysis of biologic exclusivity, patent scope and manufacturing barriers.
When do Yescarta and Tecartus lose exclusivity?
Yescarta faces the earliest major exclusivity event because it was approved in 2017. Its reference-product biologic exclusivity is expected to reach the end of its 12-year period around 2029. Tecartus is expected to reach the corresponding period around 2032.
These dates do not automatically establish generic or biosimilar launch dates.
| Product |
Approximate first approval |
Approximate 12-year biologic exclusivity milestone |
Commercial risk window |
| Yescarta |
2017 |
2029 |
2028-2032, depending on patents and litigation |
| Tecartus |
2020 |
2032 |
2031-2035, depending on patents and litigation |
CAR T biosimilar development is more difficult than conventional monoclonal-antibody biosimilar development because the product is a living cellular therapy with a patient-specific manufacturing process. A competing applicant must demonstrate analytical, manufacturing and clinical comparability while managing complex logistics.
The first meaningful erosion may therefore come from competing branded cell therapies, bispecific antibodies or next-generation constructs rather than a conventional biosimilar immediately after exclusivity expiry.
Which companies are challenging Kite’s market position?
Kite’s competitive threats come from several categories.
Direct CD19 CAR T competitors
Bristol Myers Squibb’s Breyanzi is the most direct commercial competitor in large B-cell lymphoma. Novartis’s Kymriah remains relevant in B-cell malignancies, particularly acute lymphoblastic leukemia.
BCMA CAR T therapies
Carvykti and Abecma compete in multiple myeloma. They do not directly replace Yescarta or Tecartus in CD19-positive lymphoma, but they compete for:
- Treatment-center capacity.
- Cellular-therapy manufacturing slots.
- Hospital capital.
- Physician attention.
- Referral infrastructure.
- Commercial payer budgets.
Bispecific antibodies
Mosunetuzumab, glofitamab and epcoritamab offer off-the-shelf treatment options in B-cell malignancies. Their advantages include immediate availability, repeat dosing and avoidance of individualized manufacturing. Their disadvantages include repeated administration, immune-related toxicities and different durability profiles.
Emerging cell therapies
Allogeneic CAR T products could reduce manufacturing time and improve inventory availability if developers solve persistence, graft-versus-host disease and immune-rejection problems. T-cell receptor therapies, tumor-infiltrating lymphocyte therapies and engineered natural-killer-cell products broaden the competitive field.
What patent litigation affects Kite Pharma?
The most significant historical litigation involved Juno Therapeutics and Kite’s CAR T technology.
In Juno Therapeutics, Inc. v. Kite Pharma, Inc., a jury initially awarded Juno approximately $1.2 billion after finding infringement of U.S. Patent No. 7,446,190. The Federal Circuit later held the asserted patent invalid for lack of adequate written description, eliminating the damages award. The dispute illustrated the vulnerability of broad CAR T claims that describe functional cellular products without adequately disclosing representative structural embodiments (Juno Therapeutics, Inc. v. Kite Pharma, Inc., 2021).
The ruling has strategic implications:
- Broad genus claims may face written-description scrutiny.
- CAR architecture patents require detailed technical disclosure.
- Functional claim language can be vulnerable if the specification does not support the claimed scope.
- Patent valuation should distinguish issued claims from commercially enforceable claims.
- Litigation exposure can change sharply after appellate review.
Kite also operates in a field where patent ownership may involve universities, biotechnology licensors, platform companies and former collaborators. Freedom-to-operate analysis must cover both product patents and manufacturing rights.
How strong is Kite’s patent estate?
Kite’s patent position is commercially meaningful but not unassailable.
| Patent-estate factor |
Assessment |
| Product differentiation |
Strong where claims cover the marketed CAR architecture |
| Manufacturing know-how |
Strong practical barrier, partly protected as trade secret |
| Method-of-use patents |
Moderate; value depends on label overlap and enforceability |
| Broad platform claims |
Variable; vulnerable to written-description and enablement attacks |
| Biosimilar exposure |
Lower near term than for monoclonal antibodies because of technical complexity |
| Design-around risk |
Meaningful, particularly for CAR components and processes |
| Litigation history |
Material, including the Juno dispute |
| Geographic enforceability |
Dependent on country-specific prosecution and validity |
Kite’s strongest competitive moat is the combination of patents, manufacturing scale, clinical evidence, treatment-center access and regulatory experience. Patent rights alone do not explain the company’s market position.
What manufacturing and operational barriers protect Kite?
Autologous CAR T manufacturing requires collection of a patient’s cells, transportation to a manufacturing facility, genetic modification, expansion, quality testing, return shipment and administration. Each step creates operational risk.
Kite has invested in manufacturing capacity and commercial infrastructure through facilities in the United States and Europe. The company’s Yescarta and Tecartus operations benefit from shared expertise in:
- Cell collection.
- Vector handling.
- Batch release.
- Cryogenic logistics.
- Treatment-center qualification.
- Patient scheduling.
- Adverse-event monitoring.
- Regulatory compliance.
The key manufacturing barriers are not absolute. Competitors with larger networks or decentralized manufacturing models may reduce turnaround time and improve access. Shorter manufacturing cycles could be strategically important because patients with aggressive lymphoma may deteriorate before product availability.
What licensing deals and strategic transactions shaped Kite?
Gilead acquired Kite Pharma in 2017 for approximately $11.9 billion. The transaction gave Gilead immediate access to Yescarta, Kite’s CAR T platform and its manufacturing capabilities (Gilead Sciences, 2017).
Kite’s platform originated partly from technology developed through academic and biotechnology relationships. The company’s commercial strategy has emphasized internal development, manufacturing expansion and partnerships that support regional access and treatment delivery.
The acquisition changed Gilead’s portfolio from a primarily antiviral and specialty-pharmaceutical business into a company with a major cell-therapy franchise. It also placed Kite’s products within Gilead’s balance sheet, global commercial organization and business-development strategy.
What generic or biosimilar launch scenarios exist for Kite products?
Scenario 1: No immediate biosimilar launch
This is the most plausible near-term outcome. A competitor may obtain approval but delay commercial launch because of manufacturing cost, treatment-center requirements and limited patient volume.
Scenario 2: Patent-settlement launch
A biosimilar or follow-on applicant could reach a settlement allowing entry before the full patent estate expires. The launch date would depend on the scope of the settlement, regulatory approval and the applicant’s manufacturing readiness.
Scenario 3: Construct-around competition
A competitor could launch a product with a different CAR structure while targeting the same antigen. This would avoid some composition claims but still compete directly for patients and treatment centers.
Scenario 4: Off-the-shelf displacement
Bispecific antibodies or allogeneic cell therapies could erode demand before conventional biosimilar entry. This would reduce Kite’s market share without directly infringing or copying Yescarta or Tecartus.
How much revenue is exposed to competitive erosion?
Kite’s combined Yescarta and Tecartus revenue exceeded $2 billion in 2023. Yescarta represents the greater exposure because it has the larger commercial base and faces the most direct competition in large B-cell lymphoma.
Revenue exposure depends on:
- Growth in earlier-line treatment.
- Expansion into follicular lymphoma.
- Durable response rates.
- Treatment-center capacity.
- Reimbursement.
- Manufacturing turnaround time.
- Bispecific-antibody adoption.
- Competing CAR T approvals.
- Patent and regulatory exclusivity.
A successful earlier-line strategy could offset later-line price and volume pressure. The opposite outcome would leave Kite more exposed to competition in heavily pretreated patients, where treatment access and clinical condition constrain utilization.
Key Takeaways
- Kite is a leading commercial CAR T company through Gilead’s Yescarta and Tecartus franchises.
- Yescarta is the principal revenue driver and has the strongest position in large B-cell lymphoma.
- Tecartus is strategically important in mantle cell lymphoma and adult acute lymphoblastic leukemia.
- Yescarta’s 12-year biologic exclusivity milestone is approximately 2029; Tecartus’s is approximately 2032.
- Patent analysis must cover CAR structure, manufacturing, methods of treatment and biologic patent-dispute procedures.
- The Orange Book is not the primary exclusivity source for these biologic products.
- Breyanzi is Kite’s closest direct competitor in large B-cell lymphoma.
- Bispecific antibodies may create earlier commercial pressure than biosimilars.
- Manufacturing capacity, treatment-center access and logistics are major non-patent barriers.
- The Juno litigation shows that broad CAR T patent claims can fail on written-description grounds.
- Kite’s strongest moat is the combined effect of patents, manufacturing, clinical evidence and commercial infrastructure.
FAQs
Could a biosimilar replace Yescarta after 2029?
A biosimilar could become legally and regulatorily possible around the end of the reference-product exclusivity period, but commercial entry would still depend on patent rights, FDA approval, manufacturing capacity and treatment-center adoption.
Is Yescarta protected by composition-of-matter patents?
Yescarta may be protected by claims covering specific CAR components and related cellular constructs, but the commercial strength of those claims depends on claim scope, validity, prosecution history and whether a competitor’s construct falls within the asserted claims.
Does Tecartus have a stronger patent position than Yescarta?
No categorical conclusion follows from approval dates alone. Tecartus may benefit from later-filed patents and a later biologic-exclusivity date, while Yescarta has greater commercial scale and a longer litigation and prosecution history.
Can bispecific antibodies be used instead of Yescarta?
In some approved indications, bispecific antibodies provide an alternative treatment pathway. They are not interchangeable with Yescarta, and treatment selection depends on disease setting, prior therapy, patient condition, toxicity and physician judgment.
What would most weaken Kite’s competitive position?
The greatest threats are faster manufacturing by competitors, expanded use of bispecific antibodies, successful next-generation or allogeneic CAR T products, reduced reimbursement and a competitor achieving superior outcomes in earlier-line lymphoma.
References
- Bristol Myers Squibb. (2024). 2023 annual report. https://www.bms.com
- Gilead Sciences, Inc. (2017). Gilead Sciences to acquire Kite Pharma for $11.9 billion. https://www.gilead.com
- Gilead Sciences, Inc. (2024a). 2023 annual report. https://www.gilead.com
- Juno Therapeutics, Inc. v. Kite Pharma, Inc., 10 F.4th 1330 (Fed. Cir. 2021).
- U.S. Food and Drug Administration. (2022a). FDA approves axicabtagene ciloleucel for large B-cell lymphoma. https://www.fda.gov
- U.S. Food and Drug Administration. (2023a). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- U.S. Food and Drug Administration. (2024a). Yescarta prescribing information. https://www.fda.gov
- U.S. Food and Drug Administration. (2024b). Tecartus prescribing information. https://www.fda.gov
